Revelation Biosciences, Inc. Common Stock
Symbol: REVB (NASDAQ)
Company Description:
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
- Today's Open: $2.43
- Today's High: $3.507
- Today's Low: $2.186
- Today's Volume: 1.04M
- Yesterday Close: $2.82
- Yesterday High: $2.8849
- Yesterday Low: $2.6806
- Yesterday Volume: 84.94K
- Last Min Volume: 215
- Last Min High: $2.359
- Last Min Low: $2.356
- Last Min VWAP: $2.356
- Name: Revelation Biosciences, Inc. Common Stock
- Website: https://www.revbiosciences.com
- Listed Date: 2022-01-11
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001810560
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $4.79M
- Round Lot: 100
- Outstanding Shares: 1.70M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-09 | 8-K | View |
2025-08-08 | 8-K | View |
2025-08-08 | 10-Q | View |
2025-07-09 | 8-K | View |
2025-06-25 | 8-K | View |
2025-06-09 | DEF 14A | View |
2025-06-04 | 8-K | View |
2025-05-29 | PRE 14A | View |
2025-05-29 | 424B3 | View |
2025-05-28 | EFFECT | View |
2025-05-28 | 8-K | View |
2025-05-23 | CORRESP | View |
2025-05-23 | S-1/A | View |
2025-05-22 | CORRESP | View |
2025-05-22 | CORRESP | View |
2025-05-21 | UPLOAD | View |
2025-05-20 | CORRESP | View |
2025-05-20 | S-1 | View |
2025-05-08 | 8-K | View |
2025-05-08 | 10-Q | View |